Horizon Discovery Group Plc (HZD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Horizon Discovery Group Plc (HZD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH132463D
  • |
  • Pages: 102
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Horizon Discovery Group plc (Horizon Discovery) is a life science company that discovers and develops genetically-modified cell lines using a proprietary translational genomics platform, consisting of an array of gene editing tools that help change almost any endogenous gene sequence of human or mammalian cell-lines. The company's products include cell lines, reference standards and in vivo models. It also offers services such as CRISPR screening, combination screening, in vivo assay services and cell-based assays. Horizon Discovery provides its products and services to genomic research organizations, pharmaceutical, biotechnology and diagnostic companies, and academic research centers for the formulation of customized medicines. The company operates in Austria, the UK and the US. Horizon Discovery is headquartered in Cambridge, the UK.

Horizon Discovery Group Plc (HZD)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 7

Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Horizon Discovery Group Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Horizon Discovery Group Plc, Medical Devices Deals, 2012 to YTD 2018 12

Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deal Details 17

Asset Purchase 17

Horizon Discovery Completes Acquisition of Combination High Throughput Screening from Zalicus 17

Venture Financing 18

Horizon Discovery Raises USD 10.5 Million In Final Closing Of Series C Financing 18

Partnerships 20

Horizon Discovery Enters into Licensing Agreement for Transposon Based Technology Platform 20

Horizon Discovery Enters Into Licensing Agreement With ATCC 21

Horizon Discovery Enters into Partnership 22

Horizon Discovery Enters into Co-Development Agreement with Roche Diagnostics 23

Horizon Discovery Enters into Research Agreement with Solentim 24

Horizon Discovery Enters into Agreement with Fulcrum Therapeutics 25

Horizon Discovery Enters into Agreement with Ubiquigent 26

Horizon Discovery Forms Joint Venture with Centauri Therapeutics 27

Horizon Discovery Partners with Axol Bioscience 28

Horizon Discovery Enters into Agreement with Swift Biosciences 29

Horizon Discovery Enters into Research Agreement with Redx Pharma 30

Horizon Discovery Enters into Co-Development Agreement with DefiniGEN 31

CareDx Enters into Co-Development Agreement with Horizon Discovery 32

Horizon Discovery Enters into Agreement with Thermo Fisher Scientific 33

Horizon Discovery Enters Into Marketing Agreement With Thermo Fisher 34

Horizon Discovery Enters into Distribution Agreement with Haplogen Genomics 35

Horizon Discovery Enters into Development and Commercialization Agreement with Otsuka Pharma 36

Horizon Discovery Enters Into Co-Development Agreement With Desktop Genetics 37

Crown Bioscience Enters Into Agreement With Horizon Discovery To Develop In Vivo Models For Drug Discovery 38

Horizon Discovery Enters Into R&D Agreement With UCL Institute of Neurology For rAAV-mediated Genome Editing 39

Crown Bioscience Enters Into Co-Development Agreement With Horizon Discovery 40

Horizon Discovery Enters Into Agreement With Domainex To Support Oncology Program 41

Horizon Discovery Enters Into Co-Development Agreement With Bayer Pharma For Human Isogenic Cell Lines 42

Horizon Discovery Enters Into Co-Development Agreement With H3 Biomedicine 43

Licensing Agreements 44

Horizon Discovery Enters into Licensing Agreement with US Immuno-Oncology Company 44

ATUM Enters into Licensing Agreement with Horizon Discovery 45

Horizon Discovery Enters into Licensing Agreement with ATUM 46

Horizon Discovery Group Enters into Licensing Agreement with AmplyCell 47

Horizon Discovery Enters into Licensing Agreement with Wistar Institute 48

Horizon Discovery Enters into Licensing Agreement with Servier Lab 49

LakePharma Enters into Licensing Agreement with Horizon Discovery 50

Abcam Enters into Licensing Agreement with Horizon Discovery 51

Horizon Discovery Extends Licensing Agreement with ERS Genomics 52

Horizon Discovery And AstraZeneca Enter Into Licensing Agreement To Develop Cancer Therapies 53

Horizon Discovery Group Enters into Licensing Agreement 55

Horizon Discovery Enters into Licensing Agreement with ProteoNic 56

Horizon Discovery Enters into Licensing Agreement with Stanford University 57

Horizon Discovery Enters into Licensing Agreement with Broad Institute for Crispr Gene Editing System 58

Horizon Discovery Enters Into Licensing Agreement With AstraZeneca 59

Horizon Discovery Enters Into Licensing Agreement With Harvard University For Crispr Gene Editing Technology 60

Sigma-Aldrich Enters Into Licensing Agreement With Horizon Discovery For CompoZr Zinc Finger Nuclease Technology 61

NIH Center for Regenerative Medicine Enters Into Licensing Agreement With Horizon Discovery For Genesis Technology 62

Horizon Discovery Enters Into Licensing Agreement With Rosalind Franklin University of Medicine and Science 63

Equity Offering 64

Horizon Discovery Raises USD104.6 million in Private Placement of Shares 64

Horizon Discovery Raises USD38.5 Million in Private Placement of Shares 65

Horizon Discovery Completes IPO For USD 66.7 Million 66

Acquisition 68

Horizon Discovery Acquires GE Healthcare Dharmacon from General Electric for USD85 Million 68

Horizon Discovery Acquires Haplogen Genomics for USD15 Million 70

Horizon Discovery Acquires Sage Labs for USD48 Million 71

Horizon Discovery Group Plc-Key Competitors 72

Horizon Discovery Group Plc-Key Employees 73

Horizon Discovery Group Plc-Locations And Subsidiaries 74

Head Office 74

Other Locations & Subsidiaries 74

Joint Venture 75

Recent Developments 76

Financial Announcements 76

May 08, 2018: Horizon Discovery Group: Preliminary Results for the Year Ended 31 December 2017 76

Sep 26, 2017: Horizon Discovery Group: Interim Results For The Six Months Ended 30 June 2017 77

May 30, 2017: Horizon Discovery Group: Preliminary Results for the Year Ended 31 December 2016 83

Corporate Communications 84

May 17, 2018: Horizon Discovery: Board Change 84

May 08, 2018: Horizon Discovery appoints Terry Pizzie as Chief Executive Officer 85

Mar 02, 2018: Horizon Discovery Group: Board Change 86

Feb 20, 2018: Horizon Discovery Announces Leadership Changes 87

Legal and Regulatory 88

Jul 03, 2017: Horizon Discovery announces inclusion of its Reference Standards in successful FDA approval of an oncology companion diagnostic test with leading next generation sequencing company 88

Government and Public Interest 89

Jul 17, 2017: Sphere Fluidics and Partners Win Major InnovateUK Grant to Develop the World's First Desktop Genome Editing System 89

May 22, 2017: Horizon Discovery Announces New Gene Editing Technology Platform for Research and Therapeutic Applications 90

Product News 91

Nov 14, 2017: Horizon Discovery's Dharmacon introduces Edit-R CRISPRa reagent platform for genome-wide CRISPR activation 91

Aug 01, 2017: Horizon Discovery announces release of high quality, well annotated CHO genome sequence to drive innovation in bioproduction 92

May 26, 2017: Horizon Discovery introduces four BRAF resistant melanoma PDX models 94

Mar 26, 2018: Horizon Discovery introduces whole human genome arrayed libraries to support CRISPR activation screening 95

Other Significant Developments 96

Sep 14, 2018: Horizon Discovery Edit-R crRNA libraries adopted by AstraZeneca as part of its functional genomics discovery platform 96

Mar 21, 2018: Horizon Discovery's Bioproduction cell line used as part of a successful drug (IND) filing 97

Sep 18, 2017: Horizon Discovery announces launch of Genome-Wide CRISPRi and CRISPRa Screening Services 98

May 09, 2017: Horizon Discovery Announces Update on its Immuno-Oncology Platform including Strong Uptake of Product and Service Offerings 99

Jan 24, 2017: Horizon Discovery Group: Trading Update 100

Jan 13, 2017: International Trade Minister Greg Hands visits fast-growing Cambridge life sciences company 101

Appendix 102

Methodology 102

About GlobalData 102

Contact Us 102

Disclaimer 102

List of Figures

Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9

Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Horizon Discovery Group Plc, Medical Devices Deals, 2012 to YTD 2018 12

List of Tables

Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Key Facts, 2016 2

Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Horizon Discovery Group Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Horizon Discovery Group Plc, Deals By Therapy Area, 2012 to YTD 2018 11

Horizon Discovery Group Plc, Medical Devices Deals, 2012 to YTD 2018 12

Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Horizon Discovery Completes Acquisition of Combination High Throughput Screening from Zalicus 17

Horizon Discovery Raises USD 10.5 Million In Final Closing Of Series C Financing 18

Horizon Discovery Enters into Licensing Agreement for Transposon Based Technology Platform 20

Horizon Discovery Enters Into Licensing Agreement With ATCC 21

Horizon Discovery Enters into Partnership 22

Horizon Discovery Enters into Co-Development Agreement with Roche Diagnostics 23

Horizon Discovery Enters into Research Agreement with Solentim 24

Horizon Discovery Enters into Agreement with Fulcrum Therapeutics 25

Horizon Discovery Enters into Agreement with Ubiquigent 26

Horizon Discovery Forms Joint Venture with Centauri Therapeutics 27

Horizon Discovery Partners with Axol Bioscience 28

Horizon Discovery Enters into Agreement with Swift Biosciences 29

Horizon Discovery Enters into Research Agreement with Redx Pharma 30

Horizon Discovery Enters into Co-Development Agreement with DefiniGEN 31

CareDx Enters into Co-Development Agreement with Horizon Discovery 32

Horizon Discovery Enters into Agreement with Thermo Fisher Scientific 33

Horizon Discovery Enters Into Marketing Agreement With Thermo Fisher 34

Horizon Discovery Enters into Distribution Agreement with Haplogen Genomics 35

Horizon Discovery Enters into Development and Commercialization Agreement with Otsuka Pharma 36

Horizon Discovery Enters Into Co-Development Agreement With Desktop Genetics 37

Crown Bioscience Enters Into Agreement With Horizon Discovery To Develop In Vivo Models For Drug Discovery 38

Horizon Discovery Enters Into R&D Agreement With UCL Institute of Neurology For rAAV-mediated Genome Editing 39

Crown Bioscience Enters Into Co-Development Agreement With Horizon Discovery 40

Horizon Discovery Enters Into Agreement With Domainex To Support Oncology Program 41

Horizon Discovery Enters Into Co-Development Agreement With Bayer Pharma For Human Isogenic Cell Lines 42

Horizon Discovery Enters Into Co-Development Agreement With H3 Biomedicine 43

Horizon Discovery Enters into Licensing Agreement with US Immuno-Oncology Company 44

ATUM Enters into Licensing Agreement with Horizon Discovery 45

Horizon Discovery Enters into Licensing Agreement with ATUM 46

Horizon Discovery Group Enters into Licensing Agreement with AmplyCell 47

Horizon Discovery Enters into Licensing Agreement with Wistar Institute 48

Horizon Discovery Enters into Licensing Agreement with Servier Lab 49

LakePharma Enters into Licensing Agreement with Horizon Discovery 50

Abcam Enters into Licensing Agreement with Horizon Discovery 51

Horizon Discovery Extends Licensing Agreement with ERS Genomics 52

Horizon Discovery And AstraZeneca Enter Into Licensing Agreement To Develop Cancer Therapies 53

Horizon Discovery Group Enters into Licensing Agreement 55

Horizon Discovery Enters into Licensing Agreement with ProteoNic 56

Horizon Discovery Enters into Licensing Agreement with Stanford University 57

Horizon Discovery Enters into Licensing Agreement with Broad Institute for Crispr Gene Editing System 58

Horizon Discovery Enters Into Licensing Agreement With AstraZeneca 59

Horizon Discovery Enters Into Licensing Agreement With Harvard University For Crispr Gene Editing Technology 60

Sigma-Aldrich Enters Into Licensing Agreement With Horizon Discovery For CompoZr Zinc Finger Nuclease Technology 61

NIH Center for Regenerative Medicine Enters Into Licensing Agreement With Horizon Discovery For Genesis Technology 62

Horizon Discovery Enters Into Licensing Agreement With Rosalind Franklin University of Medicine and Science 63

Horizon Discovery Raises USD104.6 million in Private Placement of Shares 64

Horizon Discovery Raises USD38.5 Million in Private Placement of Shares 65

Horizon Discovery Completes IPO For USD 66.7 Million 66

Horizon Discovery Acquires GE Healthcare Dharmacon from General Electric for USD85 Million 68

Horizon Discovery Acquires Haplogen Genomics for USD15 Million 70

Horizon Discovery Acquires Sage Labs for USD48 Million 71

Horizon Discovery Group Plc, Key Competitors 72

Horizon Discovery Group Plc, Key Employees 73

Horizon Discovery Group Plc, Other Locations 74

Horizon Discovery Group Plc, Subsidiaries 74

Horizon Discovery Group Plc, Joint Venture 75

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Horizon Discovery Group Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 18445
Site License
USD 500 INR 36890
Corporate User License
USD 750 INR 55335

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com